117.61
전일 마감가:
$117.59
열려 있는:
$115.83
하루 거래량:
645.43K
Relative Volume:
0.85
시가총액:
$6.63B
수익:
$738.26M
순이익/손실:
$48.89M
주가수익비율:
136.04
EPS:
0.8645
순현금흐름:
$91.69M
1주 성능:
+3.38%
1개월 성능:
-14.29%
6개월 성능:
-3.83%
1년 성능:
-18.82%
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
RGEN
Repligen Corp
|
117.61 | 6.62B | 738.26M | 48.89M | 91.69M | 0.8645 |
|
ISRG
Intuitive Surgical Inc
|
479.93 | 169.66B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
156.53 | 44.97B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
75.01 | 36.92B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
43.59 | 34.30B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
227.41 | 33.20B | 5.40B | 1.49B | 1.78B | 10.12 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-01 | 개시 | HSBC Securities | Buy |
| 2025-09-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
Alliancebernstein L.P. Buys 197,778 Shares of Repligen Corporation $RGEN - MarketBeat
270,000 Shares in Repligen Corporation $RGEN Acquired by Iron Triangle Partners LP - MarketBeat
Fred Alger Management LLC Boosts Position in Repligen Corporation $RGEN - MarketBeat
Repligen Corporation $RGEN Shares Acquired by Bamco Inc. NY - MarketBeat
Schroder Investment Management Group Purchases 254,212 Shares of Repligen Corporation $RGEN - MarketBeat
Repligen Corporation $RGEN Shares Sold by Blue Whale Capital LLP - MarketBeat
Repligen Corp at Leerink Global Healthcare Conference Transcript - GuruFocus
Repligen at Leerink Conference: Strategic Growth and Challenges - Investing.com
Reassessing Repligen (RGEN) Valuation After Sector Pullback And Profitability Concerns - Yahoo Finance
Evaluating Repligen (RGEN) After Sharp Share Price Declines and Conflicting Valuation Signals - Yahoo Finance
Reassessing Repligen (RGEN) Valuation After Healthcare Jobs Shock And Margin Concerns - simplywall.st
Market Moves: Whats the analyst consensus on Repligen Corporation2026 Sentiment & Expert Approved Trade Ideas - baoquankhu1.vn
AMN Healthcare Services, RadNet, Evolent Health, Repligen, and Amphastar Pharmaceuticals Stocks Trade Down, What You Need To Know - Yahoo Finance
Repligen Corporation to Present at Upcoming March Conferences - ChartMill
RGEN SEC FilingsRepligen 10-K, 10-Q, 8-K Forms - Stock Titan
Repligen Corporation $RGEN Shares Sold by TD Asset Management Inc - MarketBeat
NZS Capital LLC Has $26.30 Million Stake in Repligen Corporation $RGEN - MarketBeat
Repligen (RGEN) COO uses 3,911 shares to cover tax withholding - Stock Titan
Repligen (RGEN) CEO reports tax-withholding share dispositions in Form 4 - Stock Titan
Repligen (RGEN) director uses 9,897 shares to cover RSU taxes - Stock Titan
Repligen (RGEN) CFO stock withheld to cover RSU tax obligations - Stock Titan
Repligen (RGEN) SVP uses company shares to cover RSU taxes - Stock Titan
Repligen (RGEN) CPO has shares withheld to cover RSU tax bill - Stock Titan
Repligen Corporation (RGEN) Investor Outlook: Exploring a 44.7% Potential Upside in the Bioprocessing Sector - DirectorsTalk Interviews
Repligen Corporation $RGEN Position Boosted by Royce & Associates LP - MarketBeat
Artisan Partners Limited Partnership Has $28.44 Million Stock Holdings in Repligen Corporation $RGEN - MarketBeat
Primecap Management Co. CA Has $24.98 Million Stock Position in Repligen Corporation $RGEN - MarketBeat
Repligen (NASDAQ:RGEN) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Privia Health, Repligen, and RadNet Shares Plummet, What You Need To Know - Yahoo Finance
Repligen Corp (RGEN) Shares Down 3.09% on Feb 27 - GuruFocus
Oversold Conditions For Repligen (RGEN) - Nasdaq
Decoding Repligen Corp (RGEN): A Strategic SWOT Insight - GuruFocus
Repligen (NASDAQ: RGEN) maps 2025 bioprocessing market, debt and control risks - Stock Titan
A Glimpse Into The Expert Outlook On Repligen Through 6 Analysts - Benzinga
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Barclays Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock Price - MarketBeat
Barclays Adjusts Repligen (RGEN) Target Price Amid Overweight Ra - GuruFocus
Wells Fargo Lowers Price Target for RGEN, Maintains Overweight R - GuruFocus
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Repligen (NASDAQ:RGEN) Price Target Lowered to $180.00 at Wells Fargo & Company - MarketBeat
Evercore ISI Group Lowers Price Target for Repligen (RGEN) to $1 - GuruFocus
KeyBanc reiterates Repligen stock rating on product momentum - Investing.com
How The Repligen (RGEN) Narrative Is Shifting With New Targets M&A Plans And Products - Yahoo Finance
Repligen (RGEN) Return To Profitability Tests Bullish Growth Narrative In Q4 2025 Results - simplywall.st
Repligen Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Repligen Corp (RGEN) Q4 2025 Earnings Call Highlights: Strong Or - GuruFocus
Repligen earnings beat by $0.05, revenue topped estimates By Investing.com - Investing.com South Africa
Repligen Q4 Earnings Call Highlights - Yahoo Finance
Repligen Q4 2025 Earnings Beat Estimates, Provides 2026 OutlookNews and Statistics - IndexBox
Repligen (RGEN) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Repligen Q4 2025 earnings surpass expectations - Investing.com
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):